Platform|API|Archive|Contact
Humanexa SignalsPharmaceutical Intelligence
Subscribe
Signals
Regulatory
  • FDA
  • EMA
  • MHRA
  • PMDA
  • Health Canada
Clinical
  • Phase I
  • Phase II
  • Phase III
  • Readouts
  • Enrollment Signals
Competitive
  • Pipeline Tracking
  • Company Moves
  • Asset Intelligence
  • Landscape Reports
Markets
  • Pricing
  • Access
  • Commercial
  • Launch Tracking
M&A Watch
  • Licensing
  • Acquisitions
  • Partnerships
  • Capital Raises
StrategyCatalystsPricing
Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

  • Regulatory
  • Clinical
  • Competitive
  • Markets
  • M&A Watch
  • Strategy
  • Catalyst Tracker

Company

  • Pricing
  • Partner with us
  • Subscribe
  • Contact
  • Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

Company

pharma companies in ophthalmology

Pharmaceutical intelligence for pharma companies in ophthalmology with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals
2
Catalysts
0
Assets
2

Recent signals(2)

ClinicalJuly 19, 2026

Pilot Trial on Brain Stimulation for Vision Impairment Shows Potential for Mobility Improvement

A pilot clinical trial is assessing the effects of non-invasive brain stimulation on orientation and mobility skills in adults with vision impairment.

ClinicalJune 30, 2026

Fenofibrate Trial Aims to Prevent Worsening of Diabetic Retinopathy

A randomized trial is evaluating fenofibrate's efficacy in preventing worsening of diabetic retinopathy over 6 years.

Upcoming catalysts

No catalysts indexed for this entity yet.

Regulatory activity

No signals indexed for this entity yet.

Clinical activity(2)

Clinical
July 19, 2026

Pilot Trial on Brain Stimulation for Vision Impairment Shows Potential for Mobility Improvement

A pilot clinical trial is assessing the effects of non-invasive brain stimulation on orientation and mobility skills in adults with vision impairment.

ClinicalJune 30, 2026

Fenofibrate Trial Aims to Prevent Worsening of Diabetic Retinopathy

A randomized trial is evaluating fenofibrate's efficacy in preventing worsening of diabetic retinopathy over 6 years.

Competitive activity

No signals indexed for this entity yet.

Assets

Fenofibrate →
Pilot →

Therapeutic areas

Diabetic Retinopathy →
Ophthalmology →
Vision Impairment →

Indications

No related entities indexed yet.

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.